vs
Side-by-side financial comparison of BALCHEM CORP (BCPC) and COLLEGIUM PHARMACEUTICAL, INC (COLL). Click either name above to swap in a different company.
BALCHEM CORP is the larger business by last-quarter revenue ($270.7M vs $205.4M, roughly 1.3× COLLEGIUM PHARMACEUTICAL, INC). BALCHEM CORP runs the higher net margin — 14.9% vs 8.3%, a 6.6% gap on every dollar of revenue. On growth, COLLEGIUM PHARMACEUTICAL, INC posted the faster year-over-year revenue change (12.9% vs 8.1%). COLLEGIUM PHARMACEUTICAL, INC produced more free cash flow last quarter ($122.4M vs $33.8M). Over the past eight quarters, COLLEGIUM PHARMACEUTICAL, INC's revenue compounded faster (19.1% CAGR vs 7.5%).
Balchem Corp is a global specialty chemicals and nutritional ingredients provider that develops, manufactures and distributes application-specific products for human nutrition, animal health, pharmaceutical and industrial end markets, serving customers across North America, Europe and Asia Pacific.
Collegium Pharmaceutical, Inc. is a specialty pharmaceutical firm focused on developing and commercializing innovative, abuse-deterrent pain management therapies. Operating primarily in the U.S. market, it offers extended-release analgesics for chronic pain patients, serving providers across primary and specialty care segments.
BCPC vs COLL — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $270.7M | $205.4M |
| Net Profit | $40.3M | $17.0M |
| Gross Margin | — | 62.5% |
| Operating Margin | 20.5% | 29.6% |
| Net Margin | 14.9% | 8.3% |
| Revenue YoY | 8.1% | 12.9% |
| Net Profit YoY | 8.7% | 35.3% |
| EPS (diluted) | $1.25 | $0.48 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $270.7M | — | ||
| Q4 25 | $263.6M | $205.4M | ||
| Q3 25 | $267.6M | $209.4M | ||
| Q2 25 | $255.5M | $188.0M | ||
| Q1 25 | $250.5M | $177.8M | ||
| Q4 24 | $240.0M | $181.9M | ||
| Q3 24 | $239.9M | $159.3M | ||
| Q2 24 | $234.1M | $145.3M |
| Q1 26 | $40.3M | — | ||
| Q4 25 | $39.2M | $17.0M | ||
| Q3 25 | $40.3M | $31.5M | ||
| Q2 25 | $38.3M | $12.0M | ||
| Q1 25 | $37.1M | $2.4M | ||
| Q4 24 | $33.6M | $12.5M | ||
| Q3 24 | $33.8M | $9.3M | ||
| Q2 24 | $32.1M | $19.6M |
| Q1 26 | — | — | ||
| Q4 25 | 35.6% | 62.5% | ||
| Q3 25 | 35.7% | 61.7% | ||
| Q2 25 | 36.4% | 57.7% | ||
| Q1 25 | 35.2% | 54.8% | ||
| Q4 24 | 36.0% | 54.0% | ||
| Q3 24 | 35.6% | 60.8% | ||
| Q2 24 | 35.5% | 62.5% |
| Q1 26 | 20.5% | — | ||
| Q4 25 | 19.8% | 29.6% | ||
| Q3 25 | 20.4% | 29.7% | ||
| Q2 25 | 20.1% | 18.7% | ||
| Q1 25 | 20.4% | 12.2% | ||
| Q4 24 | 19.8% | 20.9% | ||
| Q3 24 | 20.0% | 21.9% | ||
| Q2 24 | 19.6% | 32.7% |
| Q1 26 | 14.9% | — | ||
| Q4 25 | 14.9% | 8.3% | ||
| Q3 25 | 15.1% | 15.0% | ||
| Q2 25 | 15.0% | 6.4% | ||
| Q1 25 | 14.8% | 1.4% | ||
| Q4 24 | 14.0% | 6.9% | ||
| Q3 24 | 14.1% | 5.9% | ||
| Q2 24 | 13.7% | 13.5% |
| Q1 26 | $1.25 | — | ||
| Q4 25 | $1.21 | $0.48 | ||
| Q3 25 | $1.24 | $0.84 | ||
| Q2 25 | $1.17 | $0.34 | ||
| Q1 25 | $1.13 | $0.07 | ||
| Q4 24 | $1.03 | $0.36 | ||
| Q3 24 | $1.03 | $0.27 | ||
| Q2 24 | $0.98 | $0.52 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $72.9M | $386.7M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.3B | $301.7M |
| Total Assets | $1.7B | $1.7B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $72.9M | — | ||
| Q4 25 | $74.6M | $386.7M | ||
| Q3 25 | $65.1M | $285.9M | ||
| Q2 25 | $65.4M | $222.2M | ||
| Q1 25 | $49.9M | $197.8M | ||
| Q4 24 | $49.5M | $162.8M | ||
| Q3 24 | $73.7M | $120.0M | ||
| Q2 24 | $63.7M | $271.6M |
| Q1 26 | $1.3B | — | ||
| Q4 25 | $1.3B | $301.7M | ||
| Q3 25 | $1.3B | $274.8M | ||
| Q2 25 | $1.3B | $232.2M | ||
| Q1 25 | $1.2B | $234.4M | ||
| Q4 24 | $1.1B | $228.8M | ||
| Q3 24 | $1.2B | $234.3M | ||
| Q2 24 | $1.1B | $216.6M |
| Q1 26 | $1.7B | — | ||
| Q4 25 | $1.7B | $1.7B | ||
| Q3 25 | $1.7B | $1.6B | ||
| Q2 25 | $1.7B | $1.6B | ||
| Q1 25 | $1.6B | $1.6B | ||
| Q4 24 | $1.6B | $1.7B | ||
| Q3 24 | $1.6B | $1.6B | ||
| Q2 24 | $1.6B | $1.1B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $40.1M | $123.0M |
| Free Cash FlowOCF − Capex | $33.8M | $122.4M |
| FCF MarginFCF / Revenue | 12.5% | 59.6% |
| Capex IntensityCapex / Revenue | 2.3% | 0.3% |
| Cash ConversionOCF / Net Profit | 0.99× | 7.25× |
| TTM Free Cash FlowTrailing 4 quarters | — | $327.6M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $40.1M | — | ||
| Q4 25 | $67.3M | $123.0M | ||
| Q3 25 | $65.6M | $78.4M | ||
| Q2 25 | $47.3M | $72.4M | ||
| Q1 25 | $36.5M | $55.4M | ||
| Q4 24 | $52.3M | $84.6M | ||
| Q3 24 | $51.3M | $-9.0M | ||
| Q2 24 | $45.0M | $67.4M |
| Q1 26 | $33.8M | — | ||
| Q4 25 | — | $122.4M | ||
| Q3 25 | — | $78.3M | ||
| Q2 25 | — | $72.4M | ||
| Q1 25 | — | $54.6M | ||
| Q4 24 | — | $84.1M | ||
| Q3 24 | — | $-9.2M | ||
| Q2 24 | — | $67.1M |
| Q1 26 | 12.5% | — | ||
| Q4 25 | — | 59.6% | ||
| Q3 25 | — | 37.4% | ||
| Q2 25 | — | 38.5% | ||
| Q1 25 | — | 30.7% | ||
| Q4 24 | — | 46.2% | ||
| Q3 24 | — | -5.8% | ||
| Q2 24 | — | 46.2% |
| Q1 26 | 2.3% | — | ||
| Q4 25 | — | 0.3% | ||
| Q3 25 | — | 0.1% | ||
| Q2 25 | — | 0.0% | ||
| Q1 25 | — | 0.4% | ||
| Q4 24 | — | 0.3% | ||
| Q3 24 | — | 0.2% | ||
| Q2 24 | — | 0.2% |
| Q1 26 | 0.99× | — | ||
| Q4 25 | 1.72× | 7.25× | ||
| Q3 25 | 1.63× | 2.49× | ||
| Q2 25 | 1.23× | 6.05× | ||
| Q1 25 | 0.98× | 22.92× | ||
| Q4 24 | 1.56× | 6.75× | ||
| Q3 24 | 1.52× | -0.96× | ||
| Q2 24 | 1.40× | 3.44× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
